Can Ozempic cause low blood sugar?

Yes, but the risk is small when Ozempic is used by itself. The Ozempic FDA label reports 0% severe hypoglycemia in monotherapy trials and 1.6–3.8% documented symptomatic glucose at or below 70 mg/dL. The risk goes up substantially when Ozempic is combined with insulin (16.7–29.8% with basal insulin) or a sulfonylurea (17.3–24.4%).

Can Wegovy cause hypoglycemia if I’m not diabetic?

Less commonly. The Wegovy label states hypoglycemia was not systematically captured as an adverse reaction in adult weight-loss trials in people without type 2 diabetes. A small number of serious events did occur in the cardiovascular outcomes trial, and the label flags a higher event rate in a subgroup with prior bariatric surgery. In adults with type 2 diabetes and BMI ≥27, clinically significant hypoglycemia (<54 mg/dL) was 6.2% on Wegovy injection vs. 2.5% on placebo.

Does the Wegovy pill have the same hypoglycemia risk as the Wegovy shot?

The two products are dosed and labeled separately. The 6.2% vs. 2.5% hypoglycemia number is from a Wegovy injection trial in patients with type 2 diabetes and BMI ≥27. Wegovy tablet labeling has its own glycemic-control language. Verify the current tablet label before applying injection-trial numbers to the tablet.

Does Mounjaro cause hypoglycemia?

Rarely on its own. Adult monotherapy data showed 0% glucose <54 mg/dL across all Mounjaro doses. With basal insulin, that rate was 14–19%; with sulfonylurea, 9.9–13.8%. In December 2025, Mounjaro was approved for pediatric type 2 diabetes (ages 10+); the SURPASS-PEDS trial reported Level 2 hypoglycemia (<54 mg/dL) in 15.4% of pediatric tirzepatide patients vs. 5.9% on placebo, with no severe events.

Does Zepbound cause low blood sugar?

In adults with type 2 diabetes and BMI ≥27, glucose <54 mg/dL was 4.2% on Zepbound vs. 1.3% on placebo. Among sulfonylurea users in that trial, the rate was 10.3%. In adults without type 2 diabetes (Study 1), glucose <54 mg/dL was 0.3% vs. 0% placebo.

Does Foundayo (orforglipron) cause hypoglycemia?

Foundayo, the new oral GLP-1 approved by the FDA in April 2026, can cause hypoglycemia. In a trial of adults with type 2 diabetes and BMI ≥27, plasma glucose <54 mg/dL was reported in 2% of Foundayo patients vs. 0.2% on placebo, with one severe event. Among Foundayo patients also taking a sulfonylurea, 7% reported hypoglycemia vs. 0.5% of those not on a sulfonylurea.

Is metformin + a GLP-1 likely to cause hypoglycemia?

Generally no. Metformin alone doesn’t typically cause low blood sugar — it works mostly by reducing how much glucose your liver releases, not by forcing insulin out. Across multiple GLP-1 labels, the GLP-1-plus-metformin combination shows much lower hypoglycemia rates than GLP-1-plus-insulin or GLP-1-plus-sulfonylurea.

Which medication combination should I worry about most?

GLP-1 plus a sulfonylurea (glipizide, glimepiride, glyburide) and GLP-1 plus insulin. Several FDA labels recommend considering a dose reduction of the sulfonylurea or insulin at GLP-1 initiation to reduce risk. This is a conversation for your prescriber, not a self-adjustment.

What should I do if my blood sugar is below 70 mg/dL on a GLP-1?

Use the 15-15 rule from CDC and ADA. Eat 15 grams of fast-acting carbs (4 oz juice, glucose tablets, or regular soda). Wait 15 minutes. Recheck. If still below 70 mg/dL, repeat. Once stable, eat a small protein-and-carb snack to prevent rebound. Call your prescriber after any confirmed low, especially if you are also on insulin or a sulfonylurea or recently increased your GLP-1 dose.

Should I stop my GLP-1 after one low?

Don’t make that decision alone. Call your prescriber and bring details: glucose readings, time of dose, time of meals, what you’d eaten, what other medications you take, and what symptoms you had. The fix is usually a dose adjustment to the insulin or sulfonylurea — not stopping the GLP-1.

Do I need a glucose meter if I’m on a GLP-1 for weight loss?

Most non-diabetic weight-loss users don’t keep a meter at home. If you’re having repeated symptoms that feel like lows, an over-the-counter glucose meter and strips can help you confirm what’s actually happening. If you’re on insulin or a sulfonylurea in addition to a GLP-1, a meter or CGM is more important and your prescriber will usually recommend one.

Can hypoglycemia from a GLP-1 cause permanent damage?

Severe, prolonged hypoglycemia can cause harm — that’s why severe lows are a medical emergency. Brief mild lows treated promptly with the 15-15 rule generally don’t cause lasting damage. The reason to take any low seriously isn’t that one episode will hurt you; it’s that recurring lows tell you something in your medication mix needs adjustment.

Do compounded GLP-1s have the same hypoglycemia risk as approved versions?

The risk on a compounded product is harder to predict because compounded products are not FDA-reviewed for dose accuracy or quality. Dosing errors are the FDA’s top-flagged compounding concern. If you’re using a compounded product and you’re also on insulin or a sulfonylurea, treat the hypoglycemia risk as harder to estimate, and be more cautious than you would on a name-brand product.

What about kids and teens on Mounjaro, Saxenda, Victoza, or Trulicity?

Pediatric users are a separate higher-monitoring group. Saxenda’s pediatric trial (ages 12–17, no diabetes) reported glucose <70 mg/dL with symptoms in 15.2% of Saxenda patients vs. 4.0% on placebo. Mounjaro’s SURPASS-PEDS trial (ages 10–18, type 2 diabetes on background therapy) reported Level 2 hypoglycemia in 15.4% vs. 5.9% on placebo. Victoza’s pediatric type 2 data showed 21.2% with glucose <54 mg/dL. None of these trials reported severe events. Pediatric prescribing should always include closer monitoring and prescriber-led dose coordination.

How fast does the 15-15 rule actually work on a GLP-1?

Liquid sugar (juice, regular soda, glucose gel) typically starts working within a few minutes; full effect within 15. Solid candy or food may be slower because GLP-1s slow stomach emptying. CDC’s fast-carb list prioritizes liquids and quickly-absorbed sugars for that reason. Avoid high-fat foods like chocolate or baked goods — the fat slows absorption.

If I keep getting lows, do I have to stop the medication?

Usually no. The standard fix is for your prescriber to reduce your insulin or sulfonylurea dose, not to stop the GLP-1 — unless something else is going on. Bring your glucose readings to the visit so the prescriber can see the pattern.

Does Mounjaro cause more hypoglycemia than Ozempic?

We don’t know with certainty, because Mounjaro and Ozempic have never been head-to-head tested for hypoglycemia in identical populations. In their respective monotherapy trials, severe hypoglycemia was 0% for both. The combination-therapy rates differ between trials but those differences reflect different study designs, not a fair comparison.

What’s the difference between feeling shaky from low food and a real hypo?

A real hypo usually has multiple symptoms together — shaky AND sweaty AND hungry AND fast heartbeat. It usually resolves within 10–15 minutes after eating fast-acting sugar. Feeling shaky from under-eating without an actual low blood sugar tends to come on slower and may not resolve as quickly with a small carb snack. The only way to know for sure is a glucose reading.

Safety guideFDA label dataVerified May 2026

GLP-1 Hypoglycemia Risk: A Plain-Language Guide to Low Blood Sugar by Drug and Situation

Q: Does the Wegovy pill have the same hypoglycemia risk as the Wegovy shot?

The two products are dosed and labeled separately. The 6.2% vs. 2.5% hypoglycemia number is from a Wegovy injection trial in patients with type 2 diabetes and BMI ≥27. Wegovy tablet labeling has its own glycemic-control language. Verify the current tablet label before applying injection-trial numbers to the tablet.

Q: Does Mounjaro cause hypoglycemia?

Rarely on its own. Adult monotherapy data showed 0% glucose <54 mg/dL across all Mounjaro doses. With basal insulin, that rate was 14–19%; with sulfonylurea, 9.9–13.8%. In December 2025, Mounjaro was approved for pediatric type 2 diabetes (ages 10+); the SURPASS-PEDS trial reported Level 2 hypoglycemia (<54 mg/dL) in 15.4% of pediatric tirzepatide patients vs. 5.9% on placebo, with no severe events.

Q: Does Zepbound cause low blood sugar?

In adults with type 2 diabetes and BMI ≥27, glucose <54 mg/dL was 4.2% on Zepbound vs. 1.3% on placebo. Among sulfonylurea users in that trial, the rate was 10.3%. In adults without type 2 diabetes (Study 1), glucose <54 mg/dL was 0.3% vs. 0% placebo.

Q: Does Foundayo (orforglipron) cause hypoglycemia?

Foundayo, the new oral GLP-1 approved by the FDA in April 2026, can cause hypoglycemia. In a trial of adults with type 2 diabetes and BMI ≥27, plasma glucose <54 mg/dL was reported in 2% of Foundayo patients vs. 0.2% on placebo, with one severe event. Among Foundayo patients also taking a sulfonylurea, 7% reported hypoglycemia vs. 0.5% of those not on a sulfonylurea.

Q: Is metformin + a GLP-1 likely to cause hypoglycemia?

Generally no. Metformin alone doesn’t typically cause low blood sugar — it works mostly by reducing how much glucose your liver releases, not by forcing insulin out. Across multiple GLP-1 labels, the GLP-1-plus-metformin combination shows much lower hypoglycemia rates than GLP-1-plus-insulin or GLP-1-plus-sulfonylurea.

Q: Which medication combination should I worry about most?

GLP-1 plus a sulfonylurea (glipizide, glimepiride, glyburide) and GLP-1 plus insulin. Several FDA labels recommend considering a dose reduction of the sulfonylurea or insulin at GLP-1 initiation to reduce risk. This is a conversation for your prescriber, not a self-adjustment.

Q: What should I do if my blood sugar is below 70 mg/dL on a GLP-1?

Use the 15-15 rule from CDC and ADA. Eat 15 grams of fast-acting carbs (4 oz juice, glucose tablets, or regular soda). Wait 15 minutes. Recheck. If still below 70 mg/dL, repeat. Once stable, eat a small protein-and-carb snack to prevent rebound. Call your prescriber after any confirmed low, especially if you are also on insulin or a sulfonylurea or recently increased your GLP-1 dose.

Q: Should I stop my GLP-1 after one low?

Don’t make that decision alone. Call your prescriber and bring details: glucose readings, time of dose, time of meals, what you’d eaten, what other medications you take, and what symptoms you had. The fix is usually a dose adjustment to the insulin or sulfonylurea — not stopping the GLP-1.

By The RX Index Editorial Team

Published: May 8, 2026

Bottom line, up front

GLP-1 hypoglycemia risk is usually low when the drug is used by itself, because GLP-1 medications mostly trigger insulin only when your blood sugar is already high. The risk gets real when a GLP-1 is stacked on top of insulin or a sulfonylurea (older diabetes pills like glipizide, glimepiride, or glyburide). It also gets real if you're barely eating, drinking on an empty stomach, exercising hard without fueling, recovering from bariatric surgery, or a pediatric patient on background diabetes therapy.

The symptoms of low blood sugar overlap almost perfectly with normal GLP-1 side effects. Shaky, sweaty, nauseous, dizzy, lightheaded — that's hypoglycemia. It's also Tuesday on a starting dose of Mounjaro. This page tells you which one is happening, what your actual risk is, and what to do about it.

Medical disclaimer: This page is for education only. It does not give specific dose-adjustment numbers for insulin or sulfonylurea reductions; those are individual decisions for your prescriber. Do not stop any prescribed medication based on what you read here.

Quick navigation

I think I’m low right now →
I take insulin or a sulfonylurea →
I’m not diabetic — should I worry? →
Compare drugs by hypoglycemia rate →
I just feel weird — is this a hypo or a side effect? →

First-Screen Risk Tiers: Which Group Are You In?

Your situation	Risk tier	What to do
GLP-1 alone, or with metformin only, no diabetes	Lower	Learn the symptoms. Don’t assume every shaky moment is hypoglycemia. Confirm with a meter when you can.
Type 2 diabetes on a GLP-1 + metformin only	Lower–moderate	Same as above, plus check glucose if symptoms feel new or strong.
Type 2 diabetes on a GLP-1 + insulin	Higher	Talk to your prescriber before starting or escalating. Insulin doses may need to come down.
Type 2 diabetes on a GLP-1 + sulfonylurea	Higher	Same — sulfonylurea doses may need adjustment at GLP-1 start.
Glucose below 70 mg/dL right now	Act now	15-15 rule (below). Recheck in 15 minutes.
Confused, can’t swallow, fainting, seizing, unconscious, or not improving after treatment	Emergency	Use glucagon if prescribed and someone trained is there. Call 911 if unconscious, glucagon isn’t available, or symptoms are severe.

How we built these tiers: Lower = standalone GLP-1 use without insulin, sulfonylureas, or other glucose-lowering meds. Higher = combinations the FDA flags in current labels. Act now = confirmed reading at the ADA “low” threshold (<70 mg/dL). Emergency = severe symptoms or inability to self-treat, per CDC and ADA consumer guidance.

What Is Hypoglycemia, in Actual Numbers?

Answer: Hypoglycemia means your blood glucose is too low. The CDC and American Diabetes Association use 70 mg/dL as the threshold to take action. Below 54 mg/dL is the ADA's “Level 2” threshold — clinically important hypoglycemia. Severe hypoglycemia (Level 3) means you need someone else's help, regardless of the exact number.

Level 1

Below 70 mg/dL

You can usually treat this yourself with a small fast-acting carb.

Level 2

Below 54 mg/dL

ADA’s threshold for clinically important hypoglycemia. More aggressive treatment needed.

Level 3

Severe — any number

You can’t treat yourself. Someone has to help. May involve confusion, seizure, or loss of consciousness.

Hypoglycemia unawareness is a separate, related issue. It's when your body stops giving you the warning symptoms before a low. It affects roughly 25% of people with type 1 diabetes and 10–15% of insulin- or sulfonylurea-treated type 2 diabetics. If you have it, you can drop dangerously low without feeling shaky first. A continuous glucose monitor (CGM) helps a lot here.

Why GLP-1s Usually Don't Crash Your Sugar (the Mechanism in 30 Seconds)

Answer: GLP-1 medicines copy a hormone your gut already makes. That hormone tells your pancreas to release insulin only when blood sugar is already high. When your sugar is normal or low, the trigger turns off. That's why monotherapy hypoglycemia is rare. The system breaks down when another drug forces insulin out regardless of glucose level — or when there's almost no glucose coming in at all.

Glucose-dependent insulin release

GLP-1 drugs tell your pancreas to release insulin when blood sugar is elevated. When blood sugar is low or normal, the trigger is off. This is the safety feature.

Glucagon suppression when high

They tell the pancreas to back off on glucagon (a hormone that raises blood sugar) when blood sugar is high. Same glucose-dependent logic.

Slower gastric emptying

They slow down how fast your stomach empties food into your intestine. That’s why you feel full longer — and why liquid fast-acting carbs work faster than solid food during a low.

Appetite suppression in the brain

They hit appetite centers. That’s why you eat less. That’s also why under-eating on a GLP-1 can contribute to lows, especially if you’re on insulin or a sulfonylurea.

The four ways the safeguard gets overridden

Sulfonylureas: Force insulin out independently of blood glucose. Add a GLP-1 on top, and now you’ve got two pushes on the insulin pedal.

Injected insulin: Doesn’t ask your blood sugar’s permission. It just lowers it. A GLP-1 on top adds another layer of glucose-lowering effect.

No food: Severe under-eating, prolonged fasting, or alcohol on an empty stomach can drive sugar low even on a “safe” drug.

Special populations: Bariatric surgery patients, pediatric users on background diabetes therapy, people with rare insulin-secreting tumors, and a few other edge cases.

How to Tell If You're Actually Having a Hypo (or Just Feeling Rough on a GLP-1)

Answer: Real hypoglycemia and normal GLP-1 side effects can feel almost identical — shaky, sweaty, nauseous, dizzy, weak. The only definitive test is a glucose meter reading. If you don't have a meter, improvement after fast-acting carbs is a clue, not proof. If symptoms are severe, you're on insulin or a sulfonylurea, or you can't safely swallow — don't play detective. Treat it like a low and get help.

Hypoglycemia vs. typical GLP-1 GI side effect — symptom decoder
If you feel…	More likely hypoglycemia when…	More likely GLP-1 side effect / dehydration when…
Shaky, trembling	Sudden onset. Paired with sweating, hunger, fast heartbeat. Resolves within 10–15 minutes after eating fast carbs.	Slower onset. No sweating. Doesn’t get better with carbs. May get better with rest or fluids.
Sweaty, cold, clammy	Sudden. Paired with anxiety and racing heart.	Slower onset. Paired with nausea or hot flashes.
Nauseous	Hypoglycemia rarely leads with nausea as the main symptom. Possible but unusual.	Very common, especially in the first weeks of a GLP-1 or after a dose escalation.
Dizzy, lightheaded	Sudden. Paired with hunger, pallor (looking pale), and weakness.	Worse on standing up (orthostatic from dehydration). Improves with fluids and electrolytes.
Fast or pounding heartbeat	Paired with hunger, shakiness, anxiety.	Possible from dehydration. Check pulse sitting vs. standing.
Headache	Often dull, with hunger. Improves with carbs.	Often after a dose, with nausea. May improve with fluids.
Confused, can’t think clearly	Red flag. Treat for a low immediately. Don’t wait to confirm. Get help if it doesn’t resolve fast.	Almost never from GI side effects alone. If you’re confused, treat as a low.
Suddenly ravenous	Classic hypoglycemia symptom. GLP-1s usually suppress hunger; sudden ravenous hunger is more often a low.	Less common — GLP-1s usually suppress hunger.

Confirmation hierarchy

Best: A glucose meter or CGM reading.
Useful but imperfect: Symptom improvement after fast-acting carbs.
Override everything: Confusion, seizure, fainting, can’t swallow → treat as emergency.

If you don't have a meter: drink 4 ounces of juice or eat a few glucose tablets. If you feel meaningfully better within 10–15 minutes, it was probably a low. If nothing changes, it's probably not a hypo — and it might be time to call your prescriber. Don't keep stacking sugar on yourself if symptoms aren't resolving. These symptoms can also come from dehydration, under-eating, or a panic response. See our GLP-1 nausea guide for more on distinguishing side effects from symptoms that need a call.

What to Do Right Now If You Think You're Low

Answer: Use the 15-15 rule from the CDC and ADA. Eat 15 grams of fast-acting carbohydrate. Wait 15 minutes. Recheck. If still under 70 mg/dL, repeat. Once you're stable, follow up with a small protein-and-carb snack so you don't crash again.

The 15-15 Rule (CDC and ADA)

Eat or drink 15 grams of fast carbs

4 ounces (½ cup) of juice or regular (non-diet) soda
3–4 glucose tablets
1 dose of glucose gel
1 tablespoon of sugar, honey, or syrup
Hard candies, jellybeans, or gumdrops — check the label for how much equals 15 grams

CDC note: Avoid high-fat or high-fiber foods like chocolate or baked goods — the fat and fiber slow how fast the sugar absorbs.

Wait 15 minutes

Don’t keep stacking sugar. Sit down. Don’t drive.

Recheck

If you have a meter and you’re still under 70 mg/dL, repeat with another 15 grams. If you don’t have a meter and you’re still symptomatic, repeat.

Stabilize

Once you’re back to normal, eat a small snack with both protein and carbs (a slice of toast with peanut butter, half a banana with cheese, a few crackers and turkey). This keeps you from rebounding low an hour later — which matters more on a GLP-1 because the drug is still slowing your digestion.

A note for GLP-1 users specifically: GLP-1 medications slow gastric emptying — documented in every label in the class. In practical terms, solid foods take longer to deliver their sugar than a liquid source would. Stick to CDC's list of fast-acting carbs (juice, regular soda, glucose tablets, glucose gel). Skip the chocolate bar.

Severe lows are different — this is an emergency

If your glucose is below 55 mg/dL, or you're confused, can't swallow safely, are unconscious, or have a seizure — that's not a 15-15 problem.

Don’t try to feed someone who’s unconscious. Choking risk.
Use injectable or nasal glucagon if it’s prescribed and someone trained is present. Nasal glucagon (Baqsimi) is a single squirt up the nose. Injectable glucagon comes as a kit or pre-filled pen.
Call 911 if the person is unconscious, glucagon isn’t available, no one knows how to use it, or symptoms are severe. ADA’s consumer guidance is explicit: don’t hesitate.

Most non-diabetic people on a GLP-1 don't have a glucagon kit at home, and don't typically need one. People on a GLP-1 + insulin or GLP-1 + sulfonylurea should ask their prescriber whether they should have one.

GLP-1 Hypoglycemia Risk by Drug: What the FDA Labels Actually Report

Answer: Every FDA-approved GLP-1 has a different hypoglycemia profile depending on what it's combined with. These rates are not directly comparable across drugs — different trials used different patient populations, durations, definitions, and background therapies. Use this section to spot the patterns (especially the with-insulin and with-sulfonylurea jumps), not to rank drugs.

Methodology: rates pulled from FDA prescribing information on DailyMed and accessdata.fda.gov on May 8, 2026. Some rates use <70 mg/dL (“documented symptomatic”); others use <54 mg/dL (“clinically significant” / ADA Level 2). We've noted which is which. Verify against the current label before relying on any specific number.

Semaglutide drugs: Ozempic, Wegovy, Rybelsus

Drug / situation	Hypoglycemia rate	Threshold used
Ozempic — monotherapy	1.6–3.8%; severe: 0%	≤70 mg/dL
Ozempic + basal insulin	16.7–29.8% (vs 15.2% placebo)	≤70 mg/dL
Ozempic + sulfonylurea	17.3–24.4%	≤70 mg/dL
Wegovy (injection) — adults with T2D + BMI ≥27	6.2% vs 2.5% placebo; 1 severe event (IV glucose)	<54 mg/dL
Wegovy (injection) — adults without T2D	Not systematically captured; higher in bariatric surgery subgroup vs placebo	N/A
Rybelsus — monotherapy	0% vs 1% placebo	<54 mg/dL
Rybelsus + insulin	26–30% vs 32% placebo	<54 mg/dL

Source: Ozempic, Wegovy, Rybelsus prescribing information (DailyMed, verified May 8, 2026).

Tirzepatide drugs: Mounjaro and Zepbound

Drug / situation	Hypoglycemia rate	Threshold
Mounjaro — adult monotherapy	0% across all doses (vs 1% placebo)	<54 mg/dL
Mounjaro + basal insulin (adults)	14–19% vs 13% placebo	<54 mg/dL
Mounjaro + sulfonylurea (adults, up to 104 wks)	9.9–13.8%; severe: 0–0.6%	<54 mg/dL
Mounjaro — pediatric T2D ages 10+ (SURPASS-PEDS; on metformin and/or basal insulin)	15.4% vs 5.9% placebo; no severe events	Level 2 (<54 mg/dL)
Zepbound — adults with T2D + BMI ≥27	4.2% vs 1.3% placebo	<54 mg/dL
Zepbound + sulfonylurea (same trial)	10.3% vs 2.1% without SFU	<54 mg/dL
Zepbound — adults without T2D (Study 1)	0.3% vs 0% placebo	<54 mg/dL

Source: Mounjaro prescribing information (DailyMed; current label including December 2025 pediatric update); SURPASS-PEDS, The Lancet 2025. Zepbound prescribing information (DailyMed).

Orforglipron: Foundayo (the new oral GLP-1, FDA-approved April 1, 2026)

First non-peptide oral GLP-1 receptor agonist. Same glucose-dependent mechanism; different chemistry. Approved for weight management; diabetes indication filed but not yet approved at time of this writing.

Situation	Rate	Threshold
Adults with T2D + BMI ≥27 (Trial 2)	2% vs 0.2% placebo; 1 severe event (5.5 mg group)	<54 mg/dL
Foundayo + sulfonylurea (same trial)	7% vs 0.5% without SFU	Hypoglycemia (any)

Source: Foundayo prescribing information, current 2026 label (DailyMed). For more on Foundayo, see our GLP-1 pill comparison guide.

Dulaglutide (Trulicity) — the prandial insulin data point

Situation	Rate	Threshold
Add-on to metformin	0.3–0.7%	<54 mg/dL
+ basal insulin	14.7%	<54 mg/dL
+ sulfonylurea	20–21%	Clinically significant
+ prandial (mealtime) insulin	69–77% (Trulicity 0.75 mg and 1.5 mg respectively)	<54 mg/dL

The 69–77% with prandial insulin is one of the loudest data points in the entire GLP-1 class. It doesn't mean every person on GLP-1 + mealtime insulin will crash. It does mean that combination is a high-monitoring, dose-coordination situation. Source: Trulicity prescribing information (DailyMed).

Liraglutide: Victoza and Saxenda

Drug / situation	Rate	Threshold
Victoza — adults, hypoglycemia requiring assistance	8 events total; 7 of 8 were also on a sulfonylurea	Severe
Victoza — pediatric T2D	21.2% (no severe events)	<54 mg/dL
Saxenda — adults, no T2D	0.1% vs 0.1% placebo	<54 mg/dL at clinic visits
Saxenda — adults with T2D, severe	0.7%; all events in patients also taking SFU	Severe
Saxenda — adults with T2D + sulfonylurea	28.2% vs 7.1% without SFU	<54 mg/dL
Saxenda — pediatric (ages 12–17, no diabetes)	15.2% vs 4.0% placebo (symptoms + <70 mg/dL); no severe events	<70 mg/dL with symptoms

Source: Victoza and Saxenda prescribing information (DailyMed).

Older GLP-1s: Byetta, Bydureon BCise, Adlyxin

Drug / situation	Rate	Threshold
Byetta — monotherapy	3.8–5.2% vs 1.3% placebo; severe: 0%	Overall
Byetta + sulfonylurea	14.4–35.7% vs 3.3% placebo	Overall
Bydureon BCise — without SFU	2.1%	<54 mg/dL
Bydureon BCise + sulfonylurea	25%; severe: 2.3%	<54 mg/dL
Adlyxin — monotherapy	2% vs 2% placebo	Symptomatic
Adlyxin + basal insulin ± metformin	28% vs 23% placebo	Any
Adlyxin + basal insulin + sulfonylurea	47% vs 22% placebo	Any

The 47% Adlyxin + basal insulin + sulfonylurea number is one of the clearest label illustrations of how combination therapy compounds risk. Source: Byetta, Bydureon BCise, Adlyxin prescribing information (DailyMed).

What the patterns actually tell you

1GLP-1 alone is rarely the main driver of low blood sugar. Standalone rates are small.

2Add a sulfonylurea, and the risk jumps materially — sometimes by an order of magnitude.

3Add insulin (especially mealtime insulin), and the risk can climb dramatically without coordinated dose adjustment.

The clinical fix is almost never “stop the GLP-1.” It's “lower the insulin or sulfonylurea dose at GLP-1 start, and adjust as the GLP-1 takes effect over the first few months.” That dose-coordination approach is reflected in current FDA label language across the class.

When Does the Risk Become Higher?

Answer: The two drug combinations the FDA flags hardest are GLP-1 + insulin and GLP-1 + sulfonylurea. Risk also climbs in pediatric users, people who eat very little, those with kidney disease or post-bariatric anatomy, anyone using compounded products, type 1 diabetics using GLP-1s off-label, and anyone drinking heavily on an empty stomach.

The two big medication red flags

Sulfonylureas & meglitinides

Glipizide (Glucotrol)
Glimepiride (Amaryl)
Glyburide (DiaBeta, Glynase)
Repaglinide (Prandin) — meglitinide
Nateglinide (Starlix) — same family

These drugs push your pancreas to release insulin regardless of your current glucose level. That's the opposite of how a GLP-1 works. Stack them, and you can crash.

Insulin (basal, prandial, or mixed)

Insulin just lowers your blood sugar. A GLP-1 added on top makes the existing insulin dose effectively stronger, because the GLP-1 itself adds glucose-lowering pressure, slows gastric emptying, and reduces how much you eat.

Many current FDA labels recommend considering a dose reduction of insulin or insulin secretagogues at GLP-1 initiation. Don't make that adjustment alone. It's a prescriber call.

Other risk elevators

Skipped meals / appetite suppression

GLP-1s reduce hunger. If you go from three meals a day to one nibble at lunch, your blood sugar can drop — especially if you’re also on insulin or a sulfonylurea.

Vomiting or diarrhea

Common in the first weeks. If you can’t keep food down, your glucose-lowering meds are operating on an empty tank.

Heavy exercise without fueling

Exercise lowers blood sugar. Don’t exercise on an empty stomach if you’re on a high-risk combination.

Alcohol on an empty stomach

Alcohol suppresses your liver’s ability to release stored glucose. Combine that with a GLP-1 and reduced food intake, and you’ve stacked three glucose-lowering forces.

Kidney disease

Nausea, vomiting, or diarrhea on a GLP-1 can lead to dehydration and acute kidney injury. Exenatide and lixisenatide carry more direct renal-use cautions in their labels.

Pediatric users

Saxenda pediatric data: glucose <70 mg/dL with symptoms in 15.2% vs 4.0% placebo. Mounjaro SURPASS-PEDS: Level 2 hypoglycemia in 15.4% vs 5.9% placebo.

Type 1 diabetes (off-label)

GLP-1s are not FDA-approved for type 1 diabetes. Risks include hypoglycemia from over-suppressed appetite plus existing insulin, and DKA if insulin gets reduced too much.

Prior bariatric surgery

Especially Roux-en-Y. Anatomy changes how nutrients hit the bloodstream. Some people develop reactive hypoglycemia after surgery, and adding a GLP-1 can complicate the picture.

Dose escalation timing: Most GLP-1s start low and titrate up over weeks or months. The hypoglycemia risk often rises right after a dose increase, especially if you're also losing weight (which makes existing insulin or sulfonylurea doses functionally stronger). If you've just gone up a dose and you're feeling new symptoms, that's the moment to call your prescriber — not next month.

What If I'm Not Diabetic? Should I Worry?

Answer: True hypoglycemia in non-diabetic adults using a GLP-1 alone for weight loss is uncommon. The much more common experience: feeling shaky/dizzy/nauseated and assuming it's a hypo when it's actually a normal GLP-1 GI side effect or simply not eating enough.

No-diabetes hypoglycemia signal across weight-management GLP-1s
Drug	No-diabetes hypoglycemia signal
Wegovy (semaglutide injection)	Not systematically captured in adult weight-loss trials without T2D. Small number of serious events in the cardiovascular outcomes trial. Higher event rate in bariatric surgery subgroup vs. placebo.
Zepbound (tirzepatide)	Glucose <54 mg/dL in 0.3% vs 0% placebo (Study 1, no diabetes).
Foundayo (orforglipron)	Approved for weight management. Diabetes-trial rate (2% vs 0.2%) is the cleanest published number; no-diabetes pivotal trial data still being characterized. Verify against the current label.
Saxenda (liraglutide)	Fasting glucose <54 mg/dL at clinic visits 0.1% vs 0.1% placebo (adults, no diabetes).

What “feels like a hypo but isn't” usually is, in non-diabetic users

Under-eating — the appetite suppression is working a little too well
Dehydration — common in the first weeks, especially with nausea
GI side effects of the medication itself
Anxiety — physiologically mimics the same symptoms
Dose escalation effects — symptoms tend to peak right after a step-up

When a non-diabetic person should escalate

A confirmed glucose reading <54 mg/dL
Repeated readings <70 mg/dL
Fainting, confusion, or seizure
Symptoms after bariatric surgery
Recurring lows specifically after high-carb meals (possible reactive hypoglycemia)
You’re using a compounded product and your symptoms are unpredictable

Reactive Hypoglycemia, Post-Bariatric Hypoglycemia, and Other Special Cases

Reactive hypoglycemia

Reactive hypoglycemia is when your blood sugar drops 1–3 hours after eating, often after a high-carbohydrate meal. GLP-1s can complicate this picture in both directions — they slow gastric emptying (which can blunt the post-meal spike) and reduce food intake (which means less of a glucose load). But they also affect insulin and glucagon signaling in ways that aren’t fully predictable in this population. There’s no blanket answer. It’s individual.

Post-bariatric hypoglycemia

Prevalence estimates vary: roughly 30% after Roux-en-Y gastric bypass and 10% after sleeve gastrectomy per 2026 analysis. A 2024 case report described a single patient with persistent post-bariatric reactive hypoglycemia whose symptoms improved on semaglutide. Evidence level: single case report. Not a treatment recommendation. If you’ve had bariatric surgery and you’re considering or already on a GLP-1, this is a conversation that needs an endocrinologist or bariatric specialist.

Insulinoma — rare but worth mentioning

Insulinomas are small insulin-secreting tumors of the pancreas causing unexplained hypoglycemia, typically when fasting. About 1–4 cases per million people per year. A 2025 case report in JCEM Case Reports described a patient whose severe postprandial hypoglycemia worsened after starting tirzepatide and was later diagnosed as an insulinoma. Evidence level: single case report. If you have persistent unexplained hypoglycemia on a GLP-1 — especially in fasting states, below 54 mg/dL, without a sulfonylurea or insulin — that’s an endocrinology workup.

Alcohol, Fasting, Illness, and Exercise: Situational Risks

Answer: Alcohol on an empty stomach can lower blood sugar on its own. So can fasting, intense exercise without fueling, and illness with vomiting or diarrhea. Stack any of those with a GLP-1, and you've stacked the glucose-lowering effects. None of these is forbidden — they just need a plan.

Alcohol

Don’t drink on an empty stomach. Eat first.
Start with less than you used to drink and reassess.
Keep a fast-acting carb nearby if you’re also on insulin or a sulfonylurea.
Hypoglycemia symptoms (confusion, slurred speech, sweating, lightheaded) overlap with intoxication. If you’re not sure which is which, treat for low blood sugar first.

Fasting and very-low-calorie days

GLP-1s suppress appetite enough that some people slide into accidental extended fasts.
If you’re also on insulin or a sulfonylurea, that’s where lows happen.
Plan eating like you’d plan medication: at consistent times, even if you’re not hungry.
Intermittent fasting on a GLP-1 isn’t off-limits, but it’s a higher-coordination situation if you’re on glucose-lowering meds.

Illness — sick days

Vomiting and diarrhea are common early on and can persist with fast escalation.
If you can’t keep food down for more than a day, your glucose-lowering medications keep working anyway.
Sick-day rules apply: call your prescriber. Don’t just push through.

Exercise

Exercise lowers blood sugar in most people.
If you’re on insulin or a sulfonylurea, eat first or carry a fast-acting carb for hard workouts.
Don’t exercise on an empty stomach if you’re on a high-risk combination.
See our guide on GLP-1 side effects for more situational tips.

Compounded GLP-1s: A Separate Hypoglycemia Question

Answer: Compounded semaglutide and tirzepatide products are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before marketing. Hypoglycemia risk on a compounded product is harder to predict because dose accuracy is harder to verify.

FDA-stated concern	What that means for hypoglycemia
Dosing errors (units vs. mL vs. mg)	The dose you think you’re getting may not be the dose you’re actually getting.
Salt forms not in approved drugs	Active ingredient may not behave the same way studied in trials.
Underreporting of adverse events	Safety signals harder to interpret across products.
Counterfeit / illegal online sales	Active ingredient may be wrong, too little, too much, or absent entirely.

If you're using a compounded product:

Verify the prescriber is licensed in your state and your medication is dispensed from a state-licensed pharmacy.
Don’t change doses without talking to the prescriber.
If you’re also on insulin or a sulfonylurea, the dose-uncertainty issue compounds the hypoglycemia risk. Be more cautious than you would on a name-brand product.
Stop and call your prescriber immediately if you have unexpected symptoms after a dose, especially hypoglycemia symptoms you didn’t have before.

Source: FDA's “Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” consumer page.

How to Prevent Low Blood Sugar on a GLP-1

Answer: Eat regularly, even when appetite is gone. Keep a fast-acting carb on you. Don't drink alcohol on an empty stomach. If you're on insulin or a sulfonylurea, ask your prescriber about reducing those at GLP-1 start — not after a problem. If you start having repeated lows, call your prescriber. Don't decide alone whether to stop the GLP-1.

The daily-life checklist

Eat at consistent times. Three smaller meals if a full plate makes you nauseous. The point is regular fueling, not volume.

Carry a fast-acting carb. Glucose tablets are small and don’t melt. A juice box works.

Hydrate. Dehydration mimics and worsens both hypoglycemia and GLP-1 GI side effects.

Don’t drink on an empty stomach. Eat first.

Plan dose-day differently. Don’t combine a fresh dose with skipping breakfast and a hard workout.

Avoid extreme low-carb crash diets at the same time you’re escalating a GLP-1. One change at a time.

If you exercise hard, fuel before. Especially if you’re on insulin or a sulfonylurea.

The four questions to ask your prescriber

1
“Do my insulin or sulfonylurea doses need to come down at GLP-1 start?”
2
“Should I have a glucose meter at home?”(Most non-diabetic users don’t need one. Most insulin or sulfonylurea users do.)
3
“Should I have a glucagon kit?”(Standard for high-risk diabetes patients. Not standard for non-diabetic weight-loss users.)
4
“If I have a low, what’s my action plan, and at what point do I call you?”

If your prescriber isn't able or willing to answer these in plain language, that's a flag — not about the medication, about the relationship.

What We Actually Verified for This Page

FDA Prescribing Information read directly (DailyMed and accessdata.fda.gov):

Ozempic (semaglutide injection)

Wegovy (semaglutide injection and tablets)

Rybelsus (oral semaglutide)

Mounjaro (tirzepatide; 2025/2026 label incl. pediatric)

Zepbound (tirzepatide)

Foundayo (orforglipron tablets, 2026 label)

Trulicity (dulaglutide)

Victoza (liraglutide)

Saxenda (liraglutide)

Byetta (exenatide)

Bydureon BCise (extended-release exenatide)

Adlyxin (lixisenatide)

Government and professional society guidance:

CDC: Treatment of Low Blood Sugar (Hypoglycemia)
American Diabetes Association: Low Blood Glucose (Hypoglycemia)
ADA Standards of Care in Diabetes (most recent annual update)
NIDDK: Hypoglycemia overview and Levels 1/2/3 definitions
FDA Drug Safety Communications: Concerns with Unapproved GLP-1 Drugs

Peer-reviewed literature:

Hannon TS et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS). The Lancet, 2025.
Fiore A et al. Efficacy of semaglutide in reactive hypoglycemia related to bariatric surgery. Endocrine, Metabolic and Immune Disorders – Drug Targets, 2024 (single case report).
JCEM Case Reports (December 2025): tirzepatide in a patient with insulinoma — single case report.

What we did not do:

Did not invent a clinical reviewer or put a fake review badge on this page.
Did not give specific dose-adjustment numbers — those are individual decisions for the prescriber.
Did not promote any specific brand, telehealth provider, or pharmacy.
Did not recommend stopping any prescribed medication.

Update cadence: We re-verify FDA prescribing information for each drug quarterly; new approvals or label changes trigger ad-hoc updates. Foundayo was added after FDA approval April 2026. Mounjaro pediatric language added after December 2025 label update. Last full re-verification: May 8, 2026.

Frequently Asked Questions

Can Ozempic cause low blood sugar?: Yes, but the risk is small when Ozempic is used by itself. The Ozempic FDA label reports 0% severe hypoglycemia in monotherapy trials and 1.6–3.8% documented symptomatic glucose at or below 70 mg/dL. The risk goes up substantially when Ozempic is combined with insulin (16.7–29.8% with basal insulin) or a sulfonylurea (17.3–24.4%).
Can Wegovy cause hypoglycemia if I’m not diabetic?: Less commonly. The Wegovy label states hypoglycemia was not systematically captured as an adverse reaction in adult weight-loss trials in people without type 2 diabetes. A small number of serious events did occur in the cardiovascular outcomes trial, and the label flags a higher event rate in a subgroup with prior bariatric surgery. In adults with type 2 diabetes and BMI ≥27, clinically significant hypoglycemia (<54 mg/dL) was 6.2% on Wegovy injection vs. 2.5% on placebo.
Does the Wegovy pill have the same hypoglycemia risk as the Wegovy shot?: The two products are dosed and labeled separately. The 6.2% vs. 2.5% hypoglycemia number is from a Wegovy injection trial in patients with type 2 diabetes and BMI ≥27. Wegovy tablet labeling has its own glycemic-control language. Verify the current tablet label before applying injection-trial numbers to the tablet.
Does Mounjaro cause hypoglycemia?: Rarely on its own. Adult monotherapy data showed 0% glucose <54 mg/dL across all Mounjaro doses. With basal insulin, that rate was 14–19%; with sulfonylurea, 9.9–13.8%. In December 2025, Mounjaro was approved for pediatric type 2 diabetes (ages 10+); the SURPASS-PEDS trial reported Level 2 hypoglycemia (<54 mg/dL) in 15.4% of pediatric tirzepatide patients vs. 5.9% on placebo, with no severe events.
Does Zepbound cause low blood sugar?: In adults with type 2 diabetes and BMI ≥27, glucose <54 mg/dL was 4.2% on Zepbound vs. 1.3% on placebo. Among sulfonylurea users in that trial, the rate was 10.3%. In adults without type 2 diabetes (Study 1), glucose <54 mg/dL was 0.3% vs. 0% placebo.
Does Foundayo (orforglipron) cause hypoglycemia?: Foundayo, the new oral GLP-1 approved by the FDA in April 2026, can cause hypoglycemia. In a trial of adults with type 2 diabetes and BMI ≥27, plasma glucose <54 mg/dL was reported in 2% of Foundayo patients vs. 0.2% on placebo, with one severe event. Among Foundayo patients also taking a sulfonylurea, 7% reported hypoglycemia vs. 0.5% of those not on a sulfonylurea.
Is metformin + a GLP-1 likely to cause hypoglycemia?: Generally no. Metformin alone doesn’t typically cause low blood sugar — it works mostly by reducing how much glucose your liver releases, not by forcing insulin out. Across multiple GLP-1 labels, the GLP-1-plus-metformin combination shows much lower hypoglycemia rates than GLP-1-plus-insulin or GLP-1-plus-sulfonylurea.
Which medication combination should I worry about most?: GLP-1 plus a sulfonylurea (glipizide, glimepiride, glyburide) and GLP-1 plus insulin. Several FDA labels recommend considering a dose reduction of the sulfonylurea or insulin at GLP-1 initiation to reduce risk. This is a conversation for your prescriber, not a self-adjustment.
What should I do if my blood sugar is below 70 mg/dL on a GLP-1?: Use the 15-15 rule from CDC and ADA. Eat 15 grams of fast-acting carbs (4 oz juice, glucose tablets, or regular soda). Wait 15 minutes. Recheck. If still below 70 mg/dL, repeat. Once stable, eat a small protein-and-carb snack to prevent rebound. Call your prescriber after any confirmed low, especially if you are also on insulin or a sulfonylurea or recently increased your GLP-1 dose.
Should I stop my GLP-1 after one low?: Don’t make that decision alone. Call your prescriber and bring details: glucose readings, time of dose, time of meals, what you’d eaten, what other medications you take, and what symptoms you had. The fix is usually a dose adjustment to the insulin or sulfonylurea — not stopping the GLP-1.
Do I need a glucose meter if I’m on a GLP-1 for weight loss?: Most non-diabetic weight-loss users don’t keep a meter at home. If you’re having repeated symptoms that feel like lows, an over-the-counter glucose meter and strips can help you confirm what’s actually happening. If you’re on insulin or a sulfonylurea in addition to a GLP-1, a meter or CGM is more important and your prescriber will usually recommend one.
Can hypoglycemia from a GLP-1 cause permanent damage?: Severe, prolonged hypoglycemia can cause harm — that’s why severe lows are a medical emergency. Brief mild lows treated promptly with the 15-15 rule generally don’t cause lasting damage. The reason to take any low seriously isn’t that one episode will hurt you; it’s that recurring lows tell you something in your medication mix needs adjustment.
Do compounded GLP-1s have the same hypoglycemia risk as approved versions?: The risk on a compounded product is harder to predict because compounded products are not FDA-reviewed for dose accuracy or quality. Dosing errors are the FDA’s top-flagged compounding concern. If you’re using a compounded product and you’re also on insulin or a sulfonylurea, treat the hypoglycemia risk as harder to estimate, and be more cautious than you would on a name-brand product.
What about kids and teens on Mounjaro, Saxenda, Victoza, or Trulicity?: Pediatric users are a separate higher-monitoring group. Saxenda’s pediatric trial (ages 12–17, no diabetes) reported glucose <70 mg/dL with symptoms in 15.2% of Saxenda patients vs. 4.0% on placebo. Mounjaro’s SURPASS-PEDS trial (ages 10–18, type 2 diabetes on background therapy) reported Level 2 hypoglycemia in 15.4% vs. 5.9% on placebo. Victoza’s pediatric type 2 data showed 21.2% with glucose <54 mg/dL. None of these trials reported severe events. Pediatric prescribing should always include closer monitoring and prescriber-led dose coordination.
How fast does the 15-15 rule actually work on a GLP-1?: Liquid sugar (juice, regular soda, glucose gel) typically starts working within a few minutes; full effect within 15. Solid candy or food may be slower because GLP-1s slow stomach emptying. CDC’s fast-carb list prioritizes liquids and quickly-absorbed sugars for that reason. Avoid high-fat foods like chocolate or baked goods — the fat slows absorption.
If I keep getting lows, do I have to stop the medication?: Usually no. The standard fix is for your prescriber to reduce your insulin or sulfonylurea dose, not to stop the GLP-1 — unless something else is going on. Bring your glucose readings to the visit so the prescriber can see the pattern.
Does Mounjaro cause more hypoglycemia than Ozempic?: We don’t know with certainty, because Mounjaro and Ozempic have never been head-to-head tested for hypoglycemia in identical populations. In their respective monotherapy trials, severe hypoglycemia was 0% for both. The combination-therapy rates differ between trials but those differences reflect different study designs, not a fair comparison.
What’s the difference between feeling shaky from low food and a real hypo?: A real hypo usually has multiple symptoms together — shaky AND sweaty AND hungry AND fast heartbeat. It usually resolves within 10–15 minutes after eating fast-acting sugar. Feeling shaky from under-eating without an actual low blood sugar tends to come on slower and may not resolve as quickly with a small carb snack. The only way to know for sure is a glucose reading.

A Final Word

Most people on a GLP-1 for weight loss never have a clinically significant low. Most type 2 diabetics on a GLP-1 plus metformin don't either. The people who most need to plan around hypoglycemia are those combining a GLP-1 with insulin or a sulfonylurea, and the fix is almost always dose coordination — not abandoning the medication that's helping.

If you came to this page in the middle of a low — drink some juice, sit down, recheck in 15 minutes, and call your prescriber today.

If you came to this page deciding whether to start a GLP-1 — you have the data. You also have the four questions to ask your prescriber. Take them with you.